Eggers Maren, Koburger-Janssen Torsten, Eickmann Markus, Zorn Juergen
Labor Prof. Gisela Enders MVZ GbR, Stuttgart, Germany.
Hygiene Nord GmbH, Greifswald, Germany.
Infect Dis Ther. 2018 Jun;7(2):249-259. doi: 10.1007/s40121-018-0200-7. Epub 2018 Apr 9.
Recent virus epidemics and rising antibiotic resistance highlight the importance of hygiene measures to prevent and control outbreaks. We investigated the in vitro bactericidal and virucidal efficacy of povidone-iodine (PVP-I) 7% gargle/mouthwash at defined dilution against oral and respiratory tract pathogens.
PVP-I was tested against Klebsiella pneumoniae and Streptococcus pneumoniae according to bactericidal quantitative suspension test EN13727 and against severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses (SARS-CoV and MERS-CoV), rotavirus strain Wa and influenza virus A subtype H1N1 according to virucidal quantitative suspension test EN14476. PVP-I 7% gargle/mouthwash was diluted 1:30 with water to a concentration of 0.23% (the recommended concentration for "real-life" use in Japan) and tested at room temperature under clean conditions [0.3 g/l bovine serum albumin (BSA), viruses only] and dirty conditions (3.0 g/l BSA + 3.0 ml/l erythrocytes) as an interfering substance for defined contact times (minimum 15 s). Rotavirus was tested without protein load. A ≥ 5 log (99.999%) decrease of bacteria and ≥ 4 log (99.99%) reduction in viral titre represented effective bactericidal and virucidal activity, respectively, per European standards.
PVP-I gargle/mouthwash diluted 1:30 (equivalent to a concentration of 0.23% PVP-I) showed effective bactericidal activity against Klebsiella pneumoniae and Streptococcus pneumoniae and rapidly inactivated SARS-CoV, MERS-CoV, influenza virus A (H1N1) and rotavirus after 15 s of exposure.
PVP-I 7% gargle/mouthwash showed rapid bactericidal activity and virucidal efficacy in vitro at a concentration of 0.23% PVP-I and may provide a protective oropharyngeal hygiene measure for individuals at high risk of exposure to oral and respiratory pathogens.
Mundipharma Research GmbH & Co. KG (MRG).
近期的病毒流行以及抗生素耐药性的不断上升凸显了卫生措施对预防和控制疫情的重要性。我们研究了7%聚维酮碘（PVP-I）漱口水/漱口液在规定稀释度下对口腔和呼吸道病原体的体外杀菌和杀病毒效果。
根据杀菌定量悬浮试验EN13727，对肺炎克雷伯菌和肺炎链球菌进行PVP-I测试；根据杀病毒定量悬浮试验EN14476，对严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒（SARS-CoV和MERS-CoV）、轮状病毒Wa株和甲型H1N1流感病毒进行测试。将7% PVP-I漱口水/漱口液用水按1:30稀释至浓度为0.23%（日本“实际使用”的推荐浓度），并在室温下的清洁条件[0.3 g/l牛血清白蛋白（BSA），仅针对病毒]和脏污条件（3.0 g/l BSA + 3.0 ml/l红细胞）下作为干扰物质进行规定接触时间（至少15秒）的测试。轮状病毒测试时无蛋白质负载。根据欧洲标准，细菌减少≥5 log（99.999%）和病毒滴度降低≥4 log（99.99%）分别代表有效的杀菌和杀病毒活性。
按1:30稀释（相当于0.23% PVP-I浓度）的PVP-I漱口水/漱口液对肺炎克雷伯菌和肺炎链球菌显示出有效的杀菌活性，并在接触15秒后迅速灭活SARS-CoV、MERS-CoV、甲型H1N1流感病毒和轮状病毒。
7% PVP-I漱口水/漱口液在0.23% PVP-I浓度下在体外显示出快速的杀菌活性和杀病毒效果，可能为有接触口腔和呼吸道病原体高风险的个体提供一种保护性的口咽卫生措施。
萌蒂制药研究有限公司（MRG）。
